Clovis Oncology

+$0.12 (+2.52%) Today
-$0.13 (-2.66%) As of 11:52 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CLVS and other ETFs, options, and stocks.

About CLVS

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

CEO
Patrick J. Mahaffy
Employees
429
Headquarters
Boulder, Colorado
Founded
2009

CLVS Key Statistics

Market Cap
599.52M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
5.98M
High Today
$4.96
Low Today
$4.65
Open Price
$4.75
Volume
3.45M
52 Week High
$11.10
52 Week Low
$4.08

CLVS Earnings

-$1.81
-$1.21
-$0.60
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Available Aug 4, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure